Activity of the morpholino anthracycline 3′-deamino-3′-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro

Investigational New Drugs

Volumn 13, Issue 2, 1995, Pages 125-131

  Ebrahim El Zayat, A A ^a   Izquierdo, Miguel A ^b   Clark, G M ^c   Von Hoff, Daniel D ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

anthracyclines; cloning assay; morpholino anthracyclines; MX2

Indexed keywords

3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER CELL; CELL SUSPENSION; CLONOGENIC ASSAY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; KIDNEY TUMOR; LUNG NON SMALL CELL CANCER; MELANOMA; OVARY TUMOR; PRIORITY JOURNAL; STOMACH TUMOR; TUMOR CELL; TUMOR GROWTH;

ANTIBIOTICS, ANTINEOPLASTIC; CARUBICIN; CELL DIVISION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUGS, INVESTIGATIONAL; HUMAN; NEOPLASMS; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; TUMOR STEM CELLS;

EID: 0028868753     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/BF00872860     Document Type: Article

References (27)

1. Anthracycline antibiotics in cancer therapy. Focus on drug resistance
2. Multidrug resistance in human cancer
3. The biochemistry of P-glycoprotein-mediated multidrug resistance
4. New morpholino anthracyclines, MX, MX2, and MY5
5. Antitumor activity of new morpholino anthracyclines
6. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells
7. Invitro evaluation of the new anticancer agents KT6149, MX2, SM5887, menogaril, and liblomycin using cisplatinor adriamycin-resistant human cancer cell lines
8. Effect of MX2, a new morpholino anthracycline, against experimental brain tumors
9. Resistance circumvention strategies tested in clinical leukaemia specimens using the MTT colorimetric assay
10. Comparative cardiotoxicity of doxorubicin and a morpholino anthracycline derivative (KRN8602)
11. 3′-deamino-3′-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks
12. 9-alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance
13. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistance cells
14. Establishment of a human leukemia subline resistant to the growth-inhibitory effect of 12- O-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glycoprotein-mediated multidrug resistance
15. Application of a human tumor colony-forming assay to new drug screening
16. Human tumor cloning assays: Applications in clinical oncology and new antineoplasetic agent development
17. Prospective clinical trial of a human tumor cloning system
18. Primary assay of human tumor stem cells
19. Biphasic effects of vanadium salts on in vitro tumor colony growth
20. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician
21. Role of DNA-binding in the cytotoxicity of an anthracycline, R20X2 and it morpholino analog, MX2
22. Expression of a multidrug-resistance gene in human tumors and tissues
23. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues
24. Detection of drug resistance and P-glycoprotein in human renal cell carcinomas
25. Pharmacokinetics of MX2, a new morpholino anthracycline, in CFS following intravenous injection
26. Phase I clinical study of MX2 (KRN 8602)
27. 3′-deamino-3′-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in refractory metastatic breast cancer: results of a preliminary phase II trial